eTable 4. Asthma medication of the intervention group and the control group at T0 (baseline) and T3, with number (percent).
| IG | CG | |||||||
| T0 (n = 202) | T3 (n = 181) | T0 (n = 210) | T3 (n = 206) | |||||
| ICS (single or combined preparation) | 189 | 93.6 % | 173 | 95.6 % | 195 | 92.9 % | 180 | 87.4 % |
| ICS/LABA | 160 | 79.2 % | 141 | 77.9 % | 157 | 74.8 % | 148 | 71.8 % |
| ICS single | 29 | 14.4 % | 32 | 17.7 % | 38 | 18.1 % | 32 | 15.5 % |
| OCS (in the last 7 days) | 39 | 19.3 % | 27 | 14.9 % | 26 | 12.4 % | 19 | 9.2 % |
| Montelukast | 37 | 18.3 % | 65 | 35.9 % | 34 | 16.2 % | 28 | 13.6 % |
| LAMA | 48 | 23.8 % | 80 | 44.2 % | 47 | 22.4 % | 46 | 22.3 % |
| Theophyllin | 14 | 6.9 % | 8 | 4.4 % | 8 | 3.8 % | 8 | 3.9 % |
| Omalizumab | 5 | 2.5 % | 5 | 2.8 % | 1 | 0.5 % | 4 | 1.9 % |
| Mepolizumab | 0 | 0.0 % | 1 | 0.6 % | 2 | 1.0 % | 3 | 1.5 % |
CG, control group; ICS, inhaled corticosteroids; IG, intervention group; LABA, long-acting beta2-agonists; LAMA, long-acting muscarinic antagonist; OCS, oral corticosteroids